spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Huntington's disease 

 HSMN NewsFeed - 26 Sep 2024
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Jul 2024
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 5 Jan 2024
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
Regenerative Medicine Neurosurgery Oncology FDA
 HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 29 Jul 2020
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Jul 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Apr 2019
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 3 Oct 2018
Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Jun 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 7 Jun 2017
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Apr 2017
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Apr 2017
Teva Announces FDA Approval of AUSTEDO(TM) (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Mar 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2017
Sangamo Therapeutics Announces Chief Financial Officer Succession
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jun 2016
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Dec 2015
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2015
Omidria(R) Approved for Commercialization Throughout the European Union and Additional Countries
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 15 Jul 2015
Raptor Pharmaceutical Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2015
Omidria(R) Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 30 Oct 2014
Omidria(TM) Granted Pass-Through Reimbursement Status from CMS
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 23 Oct 2014
Raptor Pharmaceutical Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2014
Omeros Receives FDA Approval of Omidria(TM) for Use in Cataract and Other Intraocular Lens Replacement Procedures
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 1 Apr 2014
Mahendra Rao, MD, PhD Joins Q Therapeutics as Chief Strategy Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 25 Mar 2014
NeuroPhage, Inc. Raises $17 Million In Series D Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 9 Jan 2014
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2013
Auspex Appoints Pratik Shah as CEO and Expands Executive Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Oct 2013
Omeros Hires Michael K. Inouye to Lead Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Sep 2013
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Aug 2013
Sangamo BioSciences to Acquire Ceregene
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2013
NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Nov 2012
Auspex Pharmaceuticals Closes $25 Million Series D Financing
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 10 Sep 2012
Raptor Pharmaceutical Corp. Expands Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Mar 2012
Raptor Pharmaceutical Corp. Announces the Appointment of Henk Doude van Troostwijk as General Manager of European Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Regenerative Medicine Neurology
 HSMN NewsFeed - 20 Sep 2011
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jun 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Feb 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Jan 2011
Raptor Pharmaceutical Hires Patrick Reichenberger to Lead Commercial Development of DR Cysteamine for Nephropathic Cystinosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Sep 2010
Pfizer to Acquire FoldRx Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Regenerative Medicine
 HSMN NewsFeed - 30 Jun 2010
Raptor Pharmaceutical Announces License Agreement for Convivia(TM)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 May 2010
BrainStorm Announces Significant Milestones Achieved and 2009 Review
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jan 2010
Neuralstem Announces First Patient Treated in ALS Stem Cell Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 30 Sep 2009
Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Sep 2009
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 29 Jul 2009
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2009
Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jul 2009
Stem Cell Therapeutics Corp. Receives Green Light to Begin Enrolling Patients in the India Phase IIb Acute Ischemic Stroke Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 15 Apr 2009
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 13 Apr 2009
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2009
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2009
Neuralstem's ALS Trial on Clinical Hold
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2008
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Biopharmaceuticals Reimbursement Distribution
 HSMN NewsFeed - 2 Dec 2008
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2008
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Nov 2008
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2008
deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Sep 2008
Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Sep 2008
Neurologix Licenses Exclusive Rights to Key Gene from Aegera Therapeutics for Use as a Potential Gene Therapy for Huntington's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 2 Sep 2008
World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board
Regenerative Medicine Personnel
 HSMN NewsFeed - 18 Aug 2008
Cambridge Laboratories Announces FDA Approval of XENAZINE(R) (tetrabenazine) in the US
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Jul 2008
Neurobiological Technologies' CEO to Retire on December 31, 2008
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Jun 2008
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 May 2008
Pipex Pharmaceuticals Receives FDA Orphan Drug Designation for Oral TTM for Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Mar 2008
Medivation Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Mar 2008
Pipex Pharmaceuticals Announces Cost Reduction Measures
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2008
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jan 2008
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2007
Amarin Announces Management Changes Including Appointment of New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 19 Nov 2007
Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Oct 2007
Rami Efrati, Former VP Business Development and Marketing for NICE SYSTEMS' Government Division, Joins BrainStorm As CEO
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 26 Sep 2007
EnVivo Pharmaceuticals Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Sep 2007
BrainStorm Cell Therapeutics Takes Initial Steps Toward FDA Submission
Regenerative Medicine Neurology
 HSMN NewsFeed - 30 Aug 2007
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2007
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
Biopharmaceuticals Devices Drug Delivery Neurology
 HSMN NewsFeed - 16 Jul 2007
BrainStorm Cell Therapeutics Elects Moshe Lion to Its Board of Directors
Regenerative Medicine Personnel
 HSMN NewsFeed - 28 Jun 2007
Avicena to Advance Huntington's Disease Clinical Program into Phase III
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jun 2007
Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 May 2007
Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
Regenerative Medicine Cardiology
 HSMN NewsFeed - 24 Apr 2007
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Apr 2007
Amarin Appoints Declan Doogan to New Position of President-Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2007
Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Mar 2007
Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Disease Conference
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2007
Amarin Expands Neurology Pipeline With Epilepsy Product Candidate
Biopharmaceuticals Drug Delivery Neurology Licensing
 HSMN NewsFeed - 27 Feb 2007
Targeted Genetics Responds to Litigation Release SEC V. Crestview Capital Partners, LLC and Stewart R. Flink
Biopharmaceuticals Litigation
 HSMN NewsFeed - 27 Feb 2007
Amarin Appoints Professor William Hall as Non-Executive Director
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 12 Feb 2007
Targeted Genetics Provides Inflammatory Arthritis Clinical Trial Update
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2007
Medivation Names Lisa Taylor Vice President of Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Nektar Appoints Howard W. Robin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Dec 2006
Sirna Therapeutics Shareholders Approve Acquisition by Merck & Co.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Dec 2006
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Dec 2006
Merck & Co. and Sirna Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period for the Proposed Acquisition of Sirna by Merck
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Dec 2006
Avicena Signs Agreement with the National Institute of Neurological Disorders and Stroke for Phase III Trial for Novel Parkinson's Disease Candidate
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Oct 2006
Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Oct 2006
Edison Pharma and Institute of Vision Enter Into Collaboration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2006
Amarin Completes Target Patient Enrollment in North American Phase III Trial of Miraxion(TM) in Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jun 2006
Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the European Rheumatology Meeting
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2006
Amarin Acquires Parkinson's Disease Drug Candidate
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 11 May 2006
Stem Cell Therapeutics Corp. Announces Issuance of Second US Patent
Regenerative Medicine
 HSMN NewsFeed - 10 May 2006
Medivation Provides Update on Huntington's Disease IND
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 May 2006
Avicena Announces Phase III ALS Trial Results
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 55

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 55 additional stories matching:
Huntington's disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.